MRI-based radiomics models for early predicting pathological response to neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis
Abstract
Abstract Objective This meta‐analysis evaluates the accuracy of MRI‐based radiomics in predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple‐negative breast cancer (TNBC) patients. Methods A systematic search of PubMed, Cochrane Library, Embase, Scopus, and Web of Science was conducted up to September 2024. Ten studies meeting inclusion criteria were assessed for methodological quality using the Radiomics Quality Score (RQS) and QUADAS‐2 tools. Pooled diagnostic performance metrics, including AUC, sensitivity, and specificity, were calculated using a fixed‐effects model. Results The fixed‐effects model yielded a pooled AUC of 0.83 (95% CI: 0.79–0.86), with sensitivity of 0.80 (95% CI: 0.68–0.88) and specificity of 0.85 (95% CI: 0.76–0.91). Support Vector Machine (SVM) and Light Gradient Boosting Machine (LightGBM) classifiers demonstrated the highest diagnostic efficacy (AUC = 0.86). Heterogeneity was low (I 2 = 32%), supporting the use of a fixed‐effects approach. Conclusion MRI‐based radiomics exhibits strong and consistent predictive performance for pCR in TNBC patients undergoing NAC, supporting its potential as a non‐invasive tool for early treatment response assessment. Further standardization and prospective validation are needed for clinical implementation.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.